{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:54:02Z","timestamp":1793732042077,"version":"4.6.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Emergency Medicine"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ajem.2025.07.042","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:46:06Z","timestamp":1753116366000},"page":"129-130","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Urgent need for reversal agents for xylazine and other imidazolines in illicit fentanyl"],"prefix":"10.1016","volume":"97","author":[{"given":"Michael E.","family":"Mullins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Seger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ajem.2025.07.042_bb0005","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.50630","article-title":"Xylazine in overdose deaths and forensic drug reports in US states, 2019-2022","volume":"7","author":"Cano","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.ajem.2025.07.042_bb0010","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annemergmed.2024.01.041","article-title":"National Institute on Drug Abuse clinical trials network meeting report: managing patients exposed to xylazine-adulterated opioids in emergency, hospital and addiction care settings","volume":"84","author":"Perrone","year":"2024","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.ajem.2025.07.042_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"4","key":"10.1016\/j.ajem.2025.07.042_bb0020","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1210\/jcem-56-4-865","article-title":"Diurnal rhythm of beta endorphin in normotensive and hypertensive patients: the effect of clonidine","volume":"56","author":"Farsang","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ajem.2025.07.042_bb0025","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/15563650.2018.1450986","article-title":"Naloxone reversal of clonidine toxicity: dose, dose, dose","volume":"56","author":"Seger","year":"2018","journal-title":"Clin Toxicol"},{"issue":"30","key":"10.1016\/j.ajem.2025.07.042_bb0030","doi-asserted-by":"crossref","first-page":"672","DOI":"10.15585\/mmwr.mm7330a3","article-title":"Detection of medetomidine among patients evaluated in emergency departments for suspected opioid overdoses \u2014 Missouri, Colorado, and Pennsylvania, September 2020\u2013December 2023","volume":"73","author":"Schwarz","year":"2024","journal-title":"Morb Mort Wkly Rep"},{"key":"10.1016\/j.ajem.2025.07.042_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2460\/ajvr.69.3.319","article-title":"Sedative and cardiopulmonary effects of medetomidine hydrochloride and xylazine hydrochloride and their reversal with atipamezole hydrochloride in calves","volume":"69","author":"Rioja","year":"2008","journal-title":"Am J Vet Res"},{"issue":"1","key":"10.1016\/j.ajem.2025.07.042_bb0045","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1365-2125.1990.tb03748.x","article-title":"Pharmacological effects and pharmacokinetics of atipamezole, a novel alpha 2-adrenoceptor antagonist--a randomized, double-blind cross-over study in healthy male volunteers","volume":"30","author":"Karhuvaara","year":"1990","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ajem.2025.07.042_bb0050","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/00000542-199809000-00005","article-title":"Reversal of the sedative and sympatholytic effects of dexmedetomidine with a specific alpha2-adrenoceptor antagonist atipamezole: a pharmacodynamic and kinetic study in healthy volunteers","volume":"89","author":"Scheinin","year":"1998","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ajem.2025.07.042_bb0055","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ajem.2017.06.054","article-title":"Atipamezole as an emergency treatment for overdose from highly concentrated alpha-2 agonists used in zoo and wildlife anesthesia","volume":"36","author":"Greenberg","year":"2018","journal-title":"Am J Emerg Med"}],"container-title":["The American Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725005030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735675725005030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T21:25:49Z","timestamp":1759872349000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735675725005030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":10,"alternative-id":["S0735675725005030"],"URL":"https:\/\/doi.org\/10.1016\/j.ajem.2025.07.042","relation":{},"ISSN":["0735-6757"],"issn-type":[{"value":"0735-6757","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urgent need for reversal agents for xylazine and other imidazolines in illicit fentanyl","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajem.2025.07.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}